Management of oral lichen planus with triamcinolone acetonide and injectable platelet-rich fibri

Not Applicable

• Conditions: Bilateral oral lichen planus lesions; Skin and Connective Tissue Diseases; Lichen planus

• Registration Number: ISRCTN11783938
• Lead Sponsor: Damascus University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-07-09
• Last Update Posted: 21 July 2021
• Study Completion: 2021-10-01

Recruitment & Eligibility

• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Patients diagnosed with oral lichen planus lesions

Exclusion Criteria

1. Patients with systemic disease
2. A history of topical therapy for oral lichen planus in the last 2 weeks or systemic treatment for oral lichen planus in the last 3 months
3. Pregnancy or lactation
4. Patients who had taken immunodepressant drugs the past 3 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain measured using a Visual Analog Scale (VAS) once a week during treatment for 4 weeks

Secondary Outcome Measures

Name	Time	Method
<br> 1. Clinical presentation of oral lichen planus measured using the REU scoring system at 1, 2, 3 and 4 weeks<br> 2. Treatment response: surface areas of erythema and ulceration measured with a sterile flexible periodontal scale probe at 1, 2, 3 and 4 weeks<br> 3. Recurrence rate measured by clinical examination at the end of treatment (day 30)<br> 4. Quality of life measured using OHIP- 14 before treatment and at the end of treatment (day 30)<br>